Syndax rises on FDA approval for blood cancer drug

Syndax Pharmaceuticals

15/11/2024 23:14

** Shares of drugmaker Syndax Pharmaceuticals  SNDX.O  rise
2% to $16.11 in after-hours trading
    ** The U.S. FDA approves revumenib, company's drug sold
under the brand name Revuforj, for treating acute leukemia with
a KMT2A translocation, a blood cancer 
    ** KMT2A translocations are chromosomal rearrangements that
involve KMT2A gene and are found in about 10% of acute leukemias
    ** Approval based on an early to mid-stage trial where the
drug showed 21% complete remission with partial recovery in the
levels of specific blood cells
    ** Syndax expects to avail 110 mg and 160 mg tablets of
Revuforj, for order in the United States, in November
    ** Up to last close, stock down 26.8% YTD

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))